You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 82 No. 1, January 1961 TABLE OF CONTENTS
  Archives
  •  Online Features
  Papers Presented at the Eighth Scientific Meeting of the North American Chapter of the International Cardiovascular Society, Miami Beach, June 11, 1960
 This Article
 •References
 •Full text PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on Web of Science (11)
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Fibrinolysin Therapy

Critical Thrombolytic Dosages and Blood Levels

HIROSHI OUCHI, M.D.; JOHN S. BELKO, M.S.; RICHARD WARREN, M.D.

AMA Arch Surg. 1961;82(1):88-96.

Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

Introduction

Recent advances in the production of potent fibrinolytic materials of human origin1 have resulted in their increasing administration to patients with thromboembolic disorders.

The doses of these materials which have been recommended have been somewhat arbitrary, since they are based on clinical trials under circumstances where the results of the trials have been difficult to assay, as is generally true in patients with thromboembolism.2 In only a few of the trials has an effort been made to correlate clinical results with peripheral blood fibrinolytic activity.2,3 This has been largely due to a lack of uniformity of methods for determining this activity.3 It has also been the result of the contention that administered plasminogen and activator disappear rapidly from the peripheral blood and join themselves to the clot, where they continue to exert fibrinolytic effects in the absence of demonstrable activity in the peripheral blood.4 . . . [Full Text PDF of this Article]


Author Affiliations

BOSTON

From Surgical Services, West Roxbury Veterans Administration and the Peter Bent Brigham Hospitals, and from the Department of Surgery, Harvard Medical School.; Fellow in Vascular Surgery, Peter Bent Brigham and West Roxbury Veterans Administration Hospitals, and Research Assistant in Surgery, Harvard Medical School (Dr. Ouchi); Chief Research Biochemist, West Roxbury Veterans Administration Hospital (Mr. Belko); Chief, Surgical Service, West Roxbury Veterans Administration Hospital, Visiting Surgeon, Peter Bent Brigham Hospital, and Clinical Professor of Surgery, Harvard Medical School (Dr. Warren).


Footnotes

Submitted for publication June 16, 1960.

Aided by PHS Grant No. H-4768.

Read before the Eighth Scientific Meeting of the International Cardiovascular Society, North American Chapter, Miami Beach, June 11, 1960.



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1961 American Medical Association. All Rights Reserved.